Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
WALTHAM, Mass., April 26, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in a fireside chat at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 2:50 p.m. ET.
A live audio webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
